In Brief: Exogen
This article was originally published in The Gray Sheet
Exogen: Health Care Financing Administration denies Medicare reimbursement coverage for the firm's Sonic Accelerated Fracture Healing System, Exogen announces Aug. 23. The Piscataway, New Jersey firm says it is "disappointed" in HCFA's determination and plans "to aggressively pursue all avenues to reverse this decision." Exogen says it presented HCFA with "clinical and economic outcome data" on 105 Medicare patients treated with the system and reported a 94% healing rate, adding that it "estimates that a significant economic benefit well above the cost of the SAFHS therapy has been realized by these patients." The firm also reports that it has not recorded any revenues from Medicare sales...
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.